JACOBIO-B (ASX: 01167) shares have risen more than 6% following the company's announcement of a share repurchase plan. At the time of writing, the stock is up 6.74% to HK$4.75, with a trading volume of HK$12.94 million.

The company has decided to exercise its share repurchase authority, allocating up to HK$100 million to buy back as many as 78.37 million of its own shares. The business operations and development are reported to be proceeding normally, with several core anti-tumor drug candidates advancing steadily in global clinical trials. Key external partnership projects are also being successfully implemented, with collaboration payments being received on schedule, and the company maintains ample liquid cash reserves.

The board of directors believes the current share price does not accurately reflect the inherent value of the company's research and development pipeline, the commercial prospects of its products, or the group's substantial cash position.

Analysts have noted that JACOBIO has successfully achieved significant milestones in commercialization, globalization, and financial health for the 2025 period, signaling its entry into a new phase of development. The company's core product, glecirasib, has been successfully launched and included in the national reimbursement drug list, leading to increased sales volume. Furthermore, the pan-KRAS inhibitor JAB-23E73 has demonstrated excellent clinical safety and efficacy, showing potential to become a first-in-class therapy.